U.S. Food and Drug Administration Center for Drug Evaluation and ResearchSkip navigation

CDER - Center for Drug Evaluation and Research Logo

Drug Information

CDER Home Site Information Comments and Feedback What's New CDER Navigation Bar

CDER ArchivesSpecific AudiencesCDER CalendarRegulatory InformationDrug InformationAbout CDERSide Navigational Buttons

Velcade (bortezomib)


The Food and Drug Administration has approved Velcade to treat a type of cancer called multiple myeloma. Velcade should only be used in people who have already been treated with two other types of chemotherapy (drugs used to kill cancer cells), and whose cancer has still progressed on the most recent therapy.  Velcade is a new type of cancer drug called a proteasome inhibitor. Proteasomes are enzymes found in cells, and play a role in regulating cell function and growth. Velcade blocks the activity of proteasomes. This blockade can lead to death of cancer cells. 


totop.gif (1525 bytes) Back to Top   Back Back to Drug Information

FDA/Center for Drug Evaluation and Research
Created: May 13, 2003; Last Updated: May 16, 2003
Originator: OTCOM/DLIS
HTML by SJW